Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The national comprehensive cancer network distress thermometer as a screening tool for the evaluation of quality of life in uveal melanoma patients.

Klingenstein A, Samel C, Garip-Kuebler A, Miller C, Liegl RG, Priglinger SG, Foerster PI.

Acta Ophthalmol. 2019 Oct 25. doi: 10.1111/aos.14277. [Epub ahead of print]

PMID:
31654488
2.

Comparison of different devices to measure the intraocular pressure in thyroid-associated orbitopathy.

Kuebler AG, Wiecha C, Reznicek L, Klingenstein A, Halfter K, Priglinger S, Hintschich C.

Graefes Arch Clin Exp Ophthalmol. 2019 Sep;257(9):2025-2032. doi: 10.1007/s00417-019-04367-2. Epub 2019 Jun 20.

PMID:
31222404
3.

Combined positron emission tomography/computed tomography for diagnosis and monitoring of orbital adnexal lymphoma.

Klingenstein A, Garip-Kuebler A, Mueller-Lisse UG, Hintschich C.

Acta Ophthalmol. 2018 Sep;96(6):e712-e717. doi: 10.1111/aos.13766. Epub 2018 Aug 26.

4.

[Update on upper eyelid blepharoplasty].

Klingenstein A, Hintschich C.

Ophthalmologe. 2018 Apr;115(4):266-274. doi: 10.1007/s00347-018-0671-7. Review. German.

PMID:
29516158
5.

Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion.

Abri Aghdam K, Reznicek L, Soltan Sanjari M, Klingenstein A, Kernt M, Seidensticker F.

Clin Ophthalmol. 2017 Feb 15;11:331-336. doi: 10.2147/OPTH.S125486. eCollection 2017.

6.

[Diagnostic Management of Exophthalmos].

Klingenstein A, Hintschich C.

Klin Monbl Augenheilkd. 2017 Jan;234(1):53-58. doi: 10.1055/s-0042-121809. Epub 2017 Jan 30. Review. German.

PMID:
28135745
7.

Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion.

Abri Aghdam K, Reznicek L, Soltan Sanjari M, Framme C, Bajor A, Klingenstein A, Kernt M, Seidensticker F.

Int J Ophthalmol. 2016 Jun 18;9(6):858-62. doi: 10.18240/ijo.2016.06.12. eCollection 2016.

8.

Combined positron emission tomography/computed tomography (PET/CT) for imaging of orbital tumours and tumours extending into the orbit.

Klingenstein A, Mueller-Lisse GU, Haug AR, Garip-Kuebler A, Miller CV, Hintschich CR.

Br J Ophthalmol. 2016 Oct;100(10):1403-8. doi: 10.1136/bjophthalmol-2015-307988. Epub 2016 Jan 14.

PMID:
26769673
9.

Evaluation of a short-term topical interferon α-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia.

Garip A, Schaumberger MM, Wolf A, Herold TR, Miller CV, Klingenstein A, Schebitz-Walter K, Hintschich CR.

Orbit. 2016;35(1):29-34. doi: 10.3109/01676830.2015.1093509. Epub 2015 Dec 4.

PMID:
26636727
10.

Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment.

Klingenstein A, Fürweger C, Mühlhofer AK, Leicht SF, Schaller UC, Muacevic A, Wowra B, Hintschich C, Eibl KH.

Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):1005-12. doi: 10.1007/s00417-015-3216-7. Epub 2015 Nov 16.

PMID:
26573389
11.

MuSIC report III: tumour microcirculation patterns and development of metastasis in long-term follow-up of melanocytic uveal tumours.

Klingenstein A, Schaumberger MM, Freeman WR, Folberg R, Mueller AJ, Schaller UC.

Acta Ophthalmol. 2016 Mar;94(2):175-81. doi: 10.1111/aos.12836. Epub 2015 Oct 1.

12.

EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model.

Wertheimer C, Siedlecki J, Kook D, Mayer WJ, Wolf A, Klingenstein A, Kampik A, Eibl-Lindner K.

Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):409-17. doi: 10.1007/s00417-014-2875-0. Epub 2014 Dec 5.

PMID:
25471020
13.

Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway.

Klingenstein A, Haug AR, Miller C, Hintschich C.

Orbit. 2015 Feb;34(1):16-22. doi: 10.3109/01676830.2014.959185. Epub 2014 Sep 29.

PMID:
25264824
14.

Clinical outcome of advanced squamous cell carcinoma of the conjunctiva.

Miller CV, Wolf A, Klingenstein A, Decker C, Garip A, Kampik A, Hintschich C.

Eye (Lond). 2014 Aug;28(8):962-7. doi: 10.1038/eye.2014.79. Epub 2014 May 23.

15.

Anterior-segment morphology and corneal biomechanical characteristics in pigmentary glaucoma.

Klingenstein A, Kernt M, Seidensticker F, Kampik A, Hirneiss C.

Clin Ophthalmol. 2014;8:119-26. doi: 10.2147/OPTH.S53088. Epub 2013 Dec 24.

16.

Quality of life in the follow-up of uveal melanoma patients after CyberKnife treatment.

Klingenstein A, Fürweger C, Nentwich MM, Schaller UC, Foerster PI, Wowra B, Muacevic A, Eibl KH.

Melanoma Res. 2013 Dec;23(6):481-8. doi: 10.1097/CMR.0000000000000023.

PMID:
24048223
17.

[Iris tumor of unknown origin].

Rueping J, Klingenstein A, Wagener J, Kampik A, Kook D.

Ophthalmologe. 2013 Dec;110(12):1185-7. doi: 10.1007/s00347-013-2797-y. German.

PMID:
23552857
18.

Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.

Klingenstein A, Haug AR, Zech CJ, Schaller UC.

Cardiovasc Intervent Radiol. 2013 Feb;36(1):158-65. doi: 10.1007/s00270-012-0373-5. Epub 2012 Apr 21.

PMID:
22526099
19.

CyberKnife radiosurgery for the treatment of orbital metastases.

Klingenstein A, Kufeld M, Wowra B, Muacevic A, Fürweger C, Schaller UC.

Technol Cancer Res Treat. 2012 Oct;11(5):433-9. Epub 2012 Jun 15.

PMID:
22475063
20.

[Persistent contact lens-associated keratitis].

Klingenstein A, Mayer WJ, Rueping J, Miller C, Kampik A, Mino De Kaspar H.

Ophthalmologe. 2011 Dec;108(12):1164-7. doi: 10.1007/s00347-011-2408-8. German.

PMID:
21842291
21.

Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.

Maier T, Laubender RP, Sturm RA, Klingenstein A, Korting HC, Ruzicka T, Berking C.

J Eur Acad Dermatol Venereol. 2012 Sep;26(9):1084-91. doi: 10.1111/j.1468-3083.2011.04210.x. Epub 2011 Aug 12.

PMID:
21838826
22.

Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.

Klingenstein A, Haritoglou I, Schaumberger MM, Nentwich MM, Hein R, Schaller UC.

Melanoma Res. 2011 Aug;21(4):352-6. doi: 10.1097/CMR.0b013e328347105e.

PMID:
21540751
23.

Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.

Klingenstein A, Haug AR, Nentwich MM, Tiling R, Schaller UC.

Melanoma Res. 2010 Dec;20(6):511-6. doi: 10.1097/CMR.0b013e3283403d6c.

PMID:
20890225
24.

[Hepatic metastases in CUP (cancer of unknown primary) and painful amaurosis].

Klingenstein A, Haug AR, Nentwich MM, Messmer EM, Schaller UC.

Ophthalmologe. 2010 Oct;107(10):947-50. doi: 10.1007/s00347-010-2131-x. German.

PMID:
20376456
25.

[Intraocular tumors in adults: uveal melanoma].

Mueller AJ, Schaller UC, Klingenstein A, Nentwich MM.

Klin Monbl Augenheilkd. 2010 Mar;227(3):R29-47; quiz R48. doi: 10.1055/s-0029-1240930. Epub 2010 Mar 16. Review. German. No abstract available.

PMID:
20234976
26.

F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers.

Haug AR, Schmidt GP, Klingenstein A, Heinemann V, Stieber P, Priebe M, la Fougère C, Becker C, Hahn K, Tiling R.

J Comput Assist Tomogr. 2007 Jul-Aug;31(4):629-34.

PMID:
17882045

Supplemental Content

Loading ...
Support Center